Category Archives: News, events, & announcements

Limited-Time Offer for VSClinical’s Cancer Add-On

We are upgrading all VSClinical +Cancer Add-On purchases to a 15-months license! One license of VSClinical +AMP Guidelines – $17,995* Additional Users: $8,995* The individualized nature of tumors requires genomic testing for providing the best outcomes for patients. Next-Gen Sequencing enables the detection of small mutations, copy number changes, and common fusions affordably and with high precision. However, the interpretation… Read more »

New eBook Release: Clinical Variant Analysis for Cancer

Applying AMP Guidelines to Analyze Somatic Variants Today, I am thrilled to share with you the launch of a brand new eBook titled “Clinical Variant Analysis for Cancer – Applying AMP Guidelines to Analyze Somatic Variants”. We would happy to send you a complimentary copy which can be requested on our website here. The clinical utilization of Next-Gen Sequencing data… Read more »

Genetic Testing for Cancer – New Version Release

Yesterday, I released a new version of my eBook, “Genetic Testing for Cancer – Third Edition”. We would be happy to send you one! To download a complimentary copy, please submit a request on our site here. In 1914, the German cytologist Theodor Boveri coined the phrase “Cancer is a disease of the genome.” At this time, his ideas were… Read more »

On Our Way to AMP Global 2019

We are looking forward to a great conference at AMP Global 2019: Global Congress on Molecular Pathology being held in Hong Kong! If you are attending the conference, we hope you will stop by our booth and say hello to the team! We would love the opportunity to connect with everyone within our community in person. This conference is especially… Read more »

Golden Helix Receives NIH-SBIR Phase 2 Grant 2R44 GM128485-02

Golden Helix, Inc. has announced themselves as the recipient of an NIH SBIR Grant 2R44GM128485-02 entitled “Automated and Guided Workflows for Clinical Testing Using NGS Assays.” “With the help of this grant, we will take the clinical automation of NGS data to the next level, focusing on germline diseases and cancer diagnostics,” states Andreas Scherer, Ph.D., President, and CEO of… Read more »